Verastem Oncology

Today, we want to celebrate our MSLs on International MSL Day. They are critical to the work we do each and every day to advance the understanding of new treatment options for patients. Thank you!

At this year's #AACR25, we’ll be sharing multiple oral and poster presentations from our development programs in the RAS/MAPK pathway. Among the preclinical data being presented, we will show how VS-7375, our potential best-in-class oral KRAS G12D (ON/OFF) inhibitor, is more potent than other KRAS G12D inhibitors. In addition, we will share preclinical data exploring how combining the mechanisms of avutometinib and defactinib inhibits RAS/MAPK pathway signaling more deeply while also blocking key adaptive resistance mechanisms including PI3K and YAP/TEAD signaling. To learn more: https://lnkd.in/epWVAwZZ #CancerResearch #VerastemOnc #KRAS #G12D

This year's SGO meeting was filled with excitement and positive energy, from the scientific forums to meaningful engagement with patients and the patient advocacy community. Today’s treatment advances are bringing forward new opportunities to research some of the hardest-to-treat and rare gynecologic cancers. At Verastem, we firmly believe that together is how we move forward and make a real difference in the lives of people living with gynecologic cancers, including low-grade serous ovarian cancer (LGSOC), a rare ovarian cancer. We are thankful to the incredible LGSOC and Ovarian Cancer patient advocacy community for spending time with us at SGO to talk about what’s possible. Thank you to: STAAR Low-Grade Serous Ovarian Cancer, Sandy Rollman Ovarian Cancer Foundation, Not These Ovaries, World Ovarian Cancer Coalition, Ovarcome, Ovarian Cancer Research Alliance ,and National Ovarian Cancer Coalition. A special thank you to the people living with LGSOC that we had the honor to spend time with at SGO. Your stories inspire and motivate us to keep working toward improving outcomes for those living with LGSOC.

Today, we announced our Q4 and full-year 2024 financial results and highlighted our recent business progress including: - our filing of a U.S. IND for VS-7375, an oral KRAS G12D (ON/OFF) inhibitor and - a progress update on our RAMP 205 trial in first-line metastatic pancreatic cancer Learn more: https://lnkd.in/erQ5EScY #VerastemOnc #cancerresearch #LGSOC #G12D #pancreaticcancer

Thank you to the Foundation for Women’s Cancer for hosting another informative Patient & Advocate Forum at the Society of Gynecologic Oncology's Annual Meeting on Women's Cancer. We were grateful for the opportunity to support the event, share our work, and most importantly listen and learn from the patient advocates and guest speakers at the event. #gynecologiconcology #SGOmtg #MultiplyYourImpact

We're happy to support this important series. Thank you Ovarcome for all that you do on behalf of people living with ovarian cancer.

Attending the Society of Gynecologic Oncology's Annual Meeting on Women’s Cancer? Visit us at booth #622 to discover more about our innovative pipeline and advancements in low-grade serous ovarian cancer (LGSOC). #LGSOC #SGOmgt #MultiplyYourImpact #VerastemOnc

Check out some of the data that will be shared at this year’s Society of Gynecologic Oncology's Annual Meeting on Women’s Cancer. #SGOmgt #MultiplyYourImpact #VerastemOnc

Today, we celebrate International Women's Day by honoring the achievements and impact of women around the globe! We are especially proud of the incredible women on our team who drive progress and advance research for RAS/MAPK pathway-driven cancers, like low-grade serous ovarian cancer (LGSOC) and other gynecological cancers. #IWD2025 #AccelerateAction #VerastemOnc

Low-grade serous ovarian cancer (LGSOC) is challenging to diagnose, as its symptoms often resemble irritable bowel syndrome (IBS). In some cases, it can take up to three years to receive an accurate LGSOC diagnosis. On #RareDiseaseDay, we recognize the obstacles that patients living with a difficult to diagnose ovarian cancer and other rare diseases face. Raising awareness is essential to improving diagnosis, treatment, and support to patients and their families. For more information, visit: https://lnkd.in/ePe7gWWi #LGSOC #OvaricanCancer #VerastemOnc